Low-dose arabinosyl cytosine in acute leukemia after a myelodysplastic syndrome and in elderly leukemia

E. P. Alessandrino, E. Orlandi, E. Brusamolino, M. Lazzarino, C. Bernasconi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Low-dose arabinosyl cytosine (ARA-C) was tested in 15 patients with acute leukemia after a myelodysplastic syndrome (MDS) and in six elderly patients with acute nonlymphoid leukemia (ANLL). The drug was given subcutaneously at 10 mg/m2, every 12 hr for 2 weeks, every 28 days. The overall response rate was 19% (one complete remission, three partial responses), and the median duration of response was 4 months. No particular features at diagnosis were predictive of response. Pancytopenia and marrow hypoplasia occurred after 44 (78%) of 56 courses of therapy and were more severe in nonresponders. Four patients died during the aplasia following ARA-C therapy. Subcutaneous low-dose ARA-C was of limited benefit and bore a noticeable hematologic toxicity.

Original languageEnglish
Pages (from-to)191-193
Number of pages3
JournalAmerican Journal of Hematology
Volume20
Issue number2
Publication statusPublished - 1985

Fingerprint

Cytosine
Myelodysplastic Syndromes
Leukemia
Pancytopenia
Bone Marrow
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology

Cite this

Alessandrino, E. P., Orlandi, E., Brusamolino, E., Lazzarino, M., & Bernasconi, C. (1985). Low-dose arabinosyl cytosine in acute leukemia after a myelodysplastic syndrome and in elderly leukemia. American Journal of Hematology, 20(2), 191-193.

Low-dose arabinosyl cytosine in acute leukemia after a myelodysplastic syndrome and in elderly leukemia. / Alessandrino, E. P.; Orlandi, E.; Brusamolino, E.; Lazzarino, M.; Bernasconi, C.

In: American Journal of Hematology, Vol. 20, No. 2, 1985, p. 191-193.

Research output: Contribution to journalArticle

Alessandrino, EP, Orlandi, E, Brusamolino, E, Lazzarino, M & Bernasconi, C 1985, 'Low-dose arabinosyl cytosine in acute leukemia after a myelodysplastic syndrome and in elderly leukemia', American Journal of Hematology, vol. 20, no. 2, pp. 191-193.
Alessandrino, E. P. ; Orlandi, E. ; Brusamolino, E. ; Lazzarino, M. ; Bernasconi, C. / Low-dose arabinosyl cytosine in acute leukemia after a myelodysplastic syndrome and in elderly leukemia. In: American Journal of Hematology. 1985 ; Vol. 20, No. 2. pp. 191-193.
@article{4d2aef23c4494192a4f15b448a10d35d,
title = "Low-dose arabinosyl cytosine in acute leukemia after a myelodysplastic syndrome and in elderly leukemia",
abstract = "Low-dose arabinosyl cytosine (ARA-C) was tested in 15 patients with acute leukemia after a myelodysplastic syndrome (MDS) and in six elderly patients with acute nonlymphoid leukemia (ANLL). The drug was given subcutaneously at 10 mg/m2, every 12 hr for 2 weeks, every 28 days. The overall response rate was 19{\%} (one complete remission, three partial responses), and the median duration of response was 4 months. No particular features at diagnosis were predictive of response. Pancytopenia and marrow hypoplasia occurred after 44 (78{\%}) of 56 courses of therapy and were more severe in nonresponders. Four patients died during the aplasia following ARA-C therapy. Subcutaneous low-dose ARA-C was of limited benefit and bore a noticeable hematologic toxicity.",
author = "Alessandrino, {E. P.} and E. Orlandi and E. Brusamolino and M. Lazzarino and C. Bernasconi",
year = "1985",
language = "English",
volume = "20",
pages = "191--193",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Low-dose arabinosyl cytosine in acute leukemia after a myelodysplastic syndrome and in elderly leukemia

AU - Alessandrino, E. P.

AU - Orlandi, E.

AU - Brusamolino, E.

AU - Lazzarino, M.

AU - Bernasconi, C.

PY - 1985

Y1 - 1985

N2 - Low-dose arabinosyl cytosine (ARA-C) was tested in 15 patients with acute leukemia after a myelodysplastic syndrome (MDS) and in six elderly patients with acute nonlymphoid leukemia (ANLL). The drug was given subcutaneously at 10 mg/m2, every 12 hr for 2 weeks, every 28 days. The overall response rate was 19% (one complete remission, three partial responses), and the median duration of response was 4 months. No particular features at diagnosis were predictive of response. Pancytopenia and marrow hypoplasia occurred after 44 (78%) of 56 courses of therapy and were more severe in nonresponders. Four patients died during the aplasia following ARA-C therapy. Subcutaneous low-dose ARA-C was of limited benefit and bore a noticeable hematologic toxicity.

AB - Low-dose arabinosyl cytosine (ARA-C) was tested in 15 patients with acute leukemia after a myelodysplastic syndrome (MDS) and in six elderly patients with acute nonlymphoid leukemia (ANLL). The drug was given subcutaneously at 10 mg/m2, every 12 hr for 2 weeks, every 28 days. The overall response rate was 19% (one complete remission, three partial responses), and the median duration of response was 4 months. No particular features at diagnosis were predictive of response. Pancytopenia and marrow hypoplasia occurred after 44 (78%) of 56 courses of therapy and were more severe in nonresponders. Four patients died during the aplasia following ARA-C therapy. Subcutaneous low-dose ARA-C was of limited benefit and bore a noticeable hematologic toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0022007303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022007303&partnerID=8YFLogxK

M3 - Article

C2 - 4036958

AN - SCOPUS:0022007303

VL - 20

SP - 191

EP - 193

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -